[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comments, Opinions, and Brief Case Reports
February 25, 2002

Aspirin, Postmenopausal Hormones, and C-Reactive Protein

Arch Intern Med. 2002;162(4):480-481. doi:

Most oral preparations of postmenopausal hormones (PMHs) increase levels of C-reactive protein (C-RP), a sensitive marker of inflammation, within about 4 weeks of initiation of therapy.13 This increase is observed in patients who are given either estrogen alone or estrogen in combination with a progestin, which has now become the most common preparation of PMH used. These data derive from observational studies and randomized trials of apparently healthy women suggesting that the increase is not attributable to atherosclerotic burden or other risk factors for cardiovascular disease or to other inflammatory disorders.4

First Page Preview View Large
First page PDF preview
First page PDF preview